Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$7.24 -0.5%	$8.18	$6.10 ▼ $28.67	$501.37M	1.46	392,143 shs	209,672 shs
DNTH Dianthus Therapeutics	$17.63 -2.8%	$19.12	$13.37 ▼ $32.27	$566.98M	1.37	261,892 shs	789,409 shs
IMNM Immunome	$8.77 -0.2%	$8.61	$5.15 ▼ $16.81	$763.08M	1.94	865,524 shs	1.07 million shs
IPHA Innate Pharma	$1.85 -3.1%	$2.08	$1.29 ▼ $3.51	$170.53M	0.26	186,470 shs	3,484 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	0.00%	-2.43%	-11.92%	-14.72%	-64.23%
DNTH Dianthus Therapeutics	0.00%	+4.63%	+1.21%	-2.81%	-31.88%
IMNM Immunome	0.00%	+0.23%	-1.02%	+30.31%	-27.52%
IPHA Innate Pharma	0.00%	+2.78%	-14.35%	+3.93%	-4.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCYC Bicycle Therapeutics	3.777 of 5 stars	4.4	4.0	2.2	2.5	0.6
DNTH Dianthus Therapeutics	1.6255 of 5 stars	3.6	0.0	2.7	1.7	0.0
IMNM Immunome	2.2061 of 5 stars	3.5	2.0	2.2	2.5	0.0
IPHA Innate Pharma	3.2527 of 5 stars	3.8	5.0	2.7	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$25.00	245.30% Upside
DNTH Dianthus Therapeutics	3.14	Buy	$53.00	200.62% Upside
IMNM Immunome	3.00	Buy	$23.33	166.06% Upside
IPHA Innate Pharma	3.50	Strong Buy	$11.00	494.59% Upside

Current Analyst Ratings Breakdown

Latest IPHA, BCYC, IMNM, and DNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	DNTH Dianthus Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$58.00 ➝ $50.00
5/13/2025	DNTH Dianthus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
5/13/2025	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00 ➝ $21.00
5/5/2025	BCYC Bicycle Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $17.00
5/2/2025	BCYC Bicycle Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$35.00 ➝ $32.00
5/2/2025	BCYC Bicycle Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$17.00 ➝ $14.00
5/2/2025	BCYC Bicycle Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$26.00 ➝ $22.00
5/2/2025	BCYC Bicycle Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$29.00 ➝ $29.00
5/1/2025	BCYC Bicycle Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $15.00
4/24/2025	IPHA Innate Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.50 ➝ $11.00
4/9/2025	BCYC Bicycle Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCYC Bicycle Therapeutics	$35.28M	14.21	N/A	N/A	$11.48 per share	0.63
DNTH Dianthus Therapeutics	$6.24M	90.86	N/A	N/A	$11.91 per share	1.48
IMNM Immunome	$9.04M	84.41	N/A	N/A	$2.27 per share	3.86
IPHA Innate Pharma	$21.77M	7.83	N/A	N/A	$0.11 per share	16.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCYC Bicycle Therapeutics	-$169.03M	-$3.14	N/A	N/A	N/A	-790.07%	-25.54%	-21.23%	8/5/2025 (Estimated)
DNTH Dianthus Therapeutics	-$84.97M	-$2.88	N/A	N/A	N/A	-1,544.23%	-29.26%	-27.87%	8/6/2025 (Estimated)
IMNM Immunome	-$292.96M	-$3.18	N/A	N/A	N/A	-1,875.21%	-71.65%	-60.36%	8/11/2025 (Estimated)
IPHA Innate Pharma	-$53.53M	N/A	0.00	∞	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)

Latest IPHA, BCYC, IMNM, and DNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	DNTH Dianthus Therapeutics	-$0.86	-$0.82	+$0.04	-$0.82	$0.81 million	$1.16 million
5/12/2025	Q1 2025	IMNM Immunome	-$0.66	-$0.52	+$0.14	-$0.52	$0.46 million	$2.93 million
5/1/2025	Q1 2025	BCYC Bicycle Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$8.67 million	$9.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCYC Bicycle Therapeutics	N/A	14.86	14.86
DNTH Dianthus Therapeutics	N/A	15.98	15.99
IMNM Immunome	N/A	10.49	10.49
IPHA Innate Pharma	2.52	2.60	2.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCYC Bicycle Therapeutics	86.15%
DNTH Dianthus Therapeutics	47.53%
IMNM Immunome	44.58%
IPHA Innate Pharma	0.16%

Insider Ownership

Company	Insider Ownership
BCYC Bicycle Therapeutics	8.50%
DNTH Dianthus Therapeutics	16.56%
IMNM Immunome	8.60%
IPHA Innate Pharma	31.89%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	63.37 million	Optionable
DNTH Dianthus Therapeutics	80	32.16 million	26.83 million	Optionable
IMNM Immunome	40	87.01 million	79.53 million	Optionable
IPHA Innate Pharma	220	92.18 million	62.78 million	Not Optionable

IPHA, BCYC, IMNM, and DNTH Headlines

Recent News About These Companies

Innate Pharma (NASDAQ:IPHA) Stock Price Down 1% - Should You Sell?

June 18, 2025 | marketbeat.com

Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences

June 17, 2025 | businesswire.com

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

June 13, 2025 | businesswire.com

Innate Pharma S.A. (NASDAQ:IPHA) Short Interest Update

May 30, 2025 | marketbeat.com

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

May 27, 2025 | businesswire.com

ASCO: Innate claims long-term lymphoma data show 'sustained effect' of anti-KIR3DL2 antibody

May 23, 2025 | fiercebiotech.comF

Outcome of Innate Pharma’s 2025 Annual General Meeting

May 23, 2025 | finance.yahoo.com

Outcome of Innate Pharma's 2025 Annual General Meeting

May 23, 2025 | businesswire.com

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

May 23, 2025 | businesswire.com

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

May 19, 2025 | businesswire.com

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

May 15, 2025 | businesswire.com

Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

May 13, 2025 | businesswire.com

Innate Pharma announces conference call and webcast for Q1 2025 business update

May 6, 2025 | businesswire.com

Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F

April 30, 2025 | businesswire.com

Innate Pharma Unveils Promising Preclinical Data for IPH4502 at AACR 2025

April 29, 2025 | tipranks.com

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting

April 29, 2025 | businesswire.com

Innate Pharma price target lowered to $11 from $11.50 at H.C. Wainwright

April 25, 2025 | markets.businessinsider.com

Innate Pharma Announces €15M Investment by Sanofi

April 24, 2025 | businesswire.com

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the Company

April 23, 2025 | businesswire.com

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025

April 16, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA, BCYC, IMNM, and DNTH Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

$7.24 -0.04 (-0.55%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$7.34 +0.10 (+1.38%)

As of 04:00 AM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Dianthus Therapeutics NASDAQ:DNTH

$17.63 -0.50 (-2.76%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$16.34 -1.29 (-7.29%)

As of 04:00 AM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Immunome NASDAQ:IMNM

$8.77 -0.02 (-0.23%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$7.42 -1.35 (-15.34%)

As of 04:00 AM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Innate Pharma NASDAQ:IPHA

$1.85 -0.06 (-3.14%)

Closing price 06/27/2025 03:57 PM Eastern

Extended Trading

$1.86 +0.00 (+0.27%)

As of 04:00 AM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time